Mostly true Certainty of evidence: moderate provisional C-CHK-07

Chickens were fed arsenical drugs (roxarsone) that raise carcinogenic inorganic arsenic in chicken meat and in consumers.

Conclusion: Arsenical feed drugs did raise arsenic in US chicken, but they were withdrawn in the US and are not authorised in the EU.

Original statement

تتغذى على أعلاف مخلوطة بمضادات حيوية وقائية، وحتى وقت قريب جداً بعقار الزرنيخ روكسارسون ... الدجاج التقليدي يحوي ضعفي إلى ثلاثة أضعاف الزرنيخ غير العضوي السام مقارنة بالعضوي، وأن الطهي يرفع تركيزه

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Chickens were fed arsenical drugs (roxarsone) that raise carcinogenic inorganic arsenic in chicken meat and in consumers.

Origin

Source status
Archive editors
Attribution
Archive editors (not Elawady)
Origin
https://eltayebat.com/rule/industrial-chicken/
Attribution uncertainty
Narrative and study selection written by the archive operators; the archive states the forbidden section is documented independently of Dr. Diaa's words.
Claimed mechanism

Organoarsenical feed additives degrade to inorganic arsenic.

Claimed health effect

Bladder and lung cancer risk.

Population concerned

general population (not specified)

Geographic restriction by Elawady

none found

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

Arsenical drugs in feed raise inorganic arsenic in chicken; conventional chicken had 2-3 times the inorganic arsenic of organic chicken; cooking concentrated it.

2. What is demonstrably correct?

Nachman et al. 2013: inorganic arsenic GM 1.8 ug/kg in conventional vs 0.6 ug/kg in organic cooked chicken; roxarsone detected in 20/40 conventional samples; cooking increased inorganic arsenic. NHANES 2003-2010: highest poultry quartile had 1.12-fold urine total arsenic. FDA documents voluntary suspension of roxarsone (3-Nitro) and withdrawal of approvals (Federal Register 22 Nov 2013; Feb 2014) and of nitarsone by end of 2015.

3. What is wrong or exaggerated?

Absolute risk was small: estimated +0.11 ug/day inorganic arsenic per 82 g serving and 3.7 additional lifetime bladder/lung cancers per 100,000 exposed persons under lifetime exposure assumptions. The practice has ended in the US; the archive's general framing ('raised on arsenical drugs') does not apply to the EU.

4. What remains unclear?

Status in Egypt and other countries that may still allow arsenicals (the FDA notes some countries still allow their use in other contexts [secondary]).

5. Which studies support it?

A-CHK-04, A-CHK-16.

6. Which studies contradict it?

I-CHK-03 (withdrawal: current US exposure via this route ended).

7. What applies to Germany and Europe?

Roxarsone is not authorised as a feed additive in the EU (secondary sources date the exclusion to 1999; primary EU instrument not verified). Under Regulation 1831/2003 only authorised feed additives may be used.

8. What is known about Egypt?

Not verified.

9. What practical conclusion is appropriate?

Correct as a historical US issue; not relevant to current EU supply.

Assessment details

Rationale for certainty of evidence

The US market-basket study and NHANES analysis support higher inorganic arsenic exposure from roxarsone-treated chicken (historical). Regulatory facts: US approvals of roxarsone, carbarsone and arsanilic acid were withdrawn in 2013/2014 and nitarsone by end of 2015 (FDA). In the EU, roxarsone is reported not to be authorised; the 1999 date is from secondary sources only. Thus true historically for the US; largely outdated today.

Source quality

Archive editorial; numbers correct; the archive itself says 'until very recently', which is accurate for the US.

Regional transferability

Low for the EU (not authorised); low for the US today (withdrawn). Egypt: regulatory status of arsenical feed additives was not verified.

Individual exceptions

Not applicable.

Regional scope of the claim
depends on production conditions
Last reviewed
25 October 2026 provisional

In plain language

The archive says US chickens were fed arsenic-based drugs that raised cancer-causing arsenic in the meat. This was true: a US study found more inorganic arsenic in conventional than organic chicken, although the estimated extra cancer risk was small (about 4 extra cases per 100,000 people over a lifetime). The USA stopped these drugs between 2013 and 2015, and they are not authorised in the EU. Whether they are used in Egypt was not verified.

Studies on this claim

Studies supporting the claim (2)

  • Arsenic in US chicken from feed drugs

    Nachman KE et al.. Environ Health Perspect 2013 · PMID 23694900 · DOI 10.1289/ehp.1206245
    Measurement / residue studycited by the Tayebat archivefull text checked★ key study

    Conventional chicken had about three times more inorganic arsenic than organic chicken; estimated extra cancer risk was small.

    Chickens were fed arsenical drugs (roxarsone) that raise carcinogenic inorganic arsenic in chicken meat and in consumers.

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    What is the arsenic species profile in US chicken and the cancer risk from arsenic-based drugs?

    How was the study done?

    Market-basket sampling of chicken meat with arsenic speciation and cancer risk estimation

    How many people, animals or samples were studied?

    116 raw and 142 cooked samples for total As; 65 raw and 78 cooked speciated; Conventional, antibiotic-free and organic retail chicken in 10 US metro areas

    What was actually found?

    Cooked: iAs GM 1.8 ug/kg (1.4-2.3) conventional vs 0.7 antibiotic-free vs 0.6 organic. Roxarsone in 20/40 conventional, 1/13 antibiotic-free, 0/25 organic. iAs 2.3 vs 0.8 ug/kg in roxarsone-positive vs negative. Cooking increased iAs. +0.11 ug/day iAs per 82 g serving; 3.7 additional lifetime bladder and lung cancers per 100,000.

    How large was the observed effect?

    Geometric means, 95% CI; risk modelling

    What do the results mean in everyday life?

    The practice has ended in the US; not used in the EU.

    What are the study's limitations?

    Single 2010-2011 US market basket before roxarsone withdrawal; breast meat only; speciation only in higher-arsenic samples; cancer risk is a model based on a draft potency value.

    What does it say about Elawady's specific claim?

    Supports the historical claim.

    Do the results apply to Germany and Europe?

    Low: not authorised in EU.

    What can explicitly not be concluded from this study?

    Cannot describe current EU or Egyptian chicken.

    Scientific details →

  • Poultry intake and arsenic in US urine

    Nigra AE et al.. Environ Health Perspect 2017 · PMID 27735790 · DOI 10.1289/EHP351
    Cross-sectional studycited by the Tayebat archiveabstract only checked

    Heavy poultry eaters had about 12% higher urine arsenic.

    Chickens were fed arsenical drugs (roxarsone) that raise carcinogenic inorganic arsenic in chicken meat and in consumers.

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Is poultry intake associated with urinary arsenic in the US population?

    How was the study done?

    Cross-sectional analysis of NHANES 2003-2010 (24-h recall and urine arsenic)

    How many people, animals or samples were studied?

    3,329 participants; US participants >=6 years with undetectable arsenobetaine

    What was actually found?

    Highest quartile: total arsenic GMR 1.12 (1.04-1.22), DMA 1.13 (1.06-1.20). Turkey fall/winter: 1.17 (0.99-1.39), p-trend 0.02.

    How large was the observed effect?

    Geometric mean ratios

    What do the results mean in everyday life?

    A historical US exposure route.

    What are the study's limitations?

    Single 24-h recall; Cross-sectional

    What does it say about Elawady's specific claim?

    Supports.

    Do the results apply to Germany and Europe?

    Low.

    What can explicitly not be concluded from this study?

    Cannot show disease.

    Scientific details →

Studies contradicting or limiting the claim (1)

  • US withdrawal of arsenic drugs for poultry

    US Food and Drug Administration. FDA 2022
    Guideline / position statementindependent cross-checkfull text checked

    Arsenic-based poultry drugs were withdrawn in the US between 2013 and 2015.

    Chickens were fed arsenical drugs (roxarsone) that raise carcinogenic inorganic arsenic in chicken meat and in consumers.

    Does the study support the specific claim? Partly · Methodological quality: not applicable · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Regulatory status of arsenical drugs in US poultry

    How was the study done?

    Regulatory information page

    How many people, animals or samples were studied?

    Not applicable; US poultry

    What was actually found?

    Alpharma voluntarily suspended sale of 3-Nitro (roxarsone); Federal Register 22 Nov 2013 withdrawal of approvals for carbarsone and roxarsone; on 27 Feb 2014 Zoetis withdrew the 3-Nitro application and sponsors withdrew approvals for arsanilic acid and carbarsone; nitarsone (Histostat) approval withdrawal requested by end of 2015, not available from the 2016 season.

    How large was the observed effect?

    Not applicable

    What do the results mean in everyday life?

    US chicken is no longer raised with these drugs.

    What are the study's limitations?

    Page does not cover other countries

    What does it say about Elawady's specific claim?

    Confirms the claim is historical.

    Do the results apply to Germany and Europe?

    EU: roxarsone not authorised (secondary sources date this to 1999; primary instrument not verified).

    What can explicitly not be concluded from this study?

    Says nothing about Egypt.

    Scientific details →

Studies with mixed or unclear results (1)

  • EU ban on antibiotic growth promoters

    European Parliament and Council. Official Journal of the EU (copy at legislation.gov.uk) 2003
    Guideline / position statementindependent cross-checkfull text checked

    Since 2006, antibiotics may not be used as growth-promoting feed additives in the EU.

    Chickens were fed arsenical drugs (roxarsone) that raise carcinogenic inorganic arsenic in chicken meat and in consumers.

    Does the study support the specific claim? No · Methodological quality: not applicable · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Rules for feed additives including phase-out of antibiotic growth promoters

    How was the study done?

    EU regulation

    How many people, animals or samples were studied?

    Not applicable; EU animal feed

    What was actually found?

    Article 11(2): antibiotics, other than coccidiostats and histomonostats, may be marketed and used as feed additives only until 31 December 2005; from 1 January 2006 deleted from the Register. Recital 25 cites the Scientific Steering Committee: growth-promoting antimicrobials from classes used in medicine should be phased out.

    How large was the observed effect?

    Not applicable

    What do the results mean in everyday life?

    "Routine antibiotics for growth" is not legal in the EU.

    What are the study's limitations?

    Therapeutic and prophylactic veterinary use regulated separately (not covered)

    What does it say about Elawady's specific claim?

    Limits the claim for the EU.

    Do the results apply to Germany and Europe?

    Directly EU.

    What can explicitly not be concluded from this study?

    Does not cover therapeutic use.

    Scientific details →

Regional context

Germany / EU

Roxarsone is not authorised as a feed additive in the EU (secondary sources date the exclusion to 1999; primary EU instrument not verified). Under Regulation 1831/2003 only authorised feed additives may be used.

Egypt

Not verified.

What applies in my country?

General scientific assessment

Mostly true Arsenical feed drugs did raise arsenic in US chicken, but they were withdrawn in the US and are not authorised in the EU.

The following areas of food safety are relevant to this statement:

  • Pesticides and pesticide residues
  • Veterinary medicines and antibiotics
  • Hormonal growth promoters
  • Contaminants (heavy metals, PFAS, PCBs, dioxins, nitrate)
  • Pathogens (Salmonella, Campylobacter, etc.)
  • Animal husbandry and feed
  • Controls, imports, recalls, labelling

Eggs · Poultry · Dairy · Fish and seafood · Red meat · Fruit and vegetables

Choose a country to see the checked information for it.

Limits: legal rules describe what is allowed, not what every single food contains. Measurement data come from samples and are meaningful only together with their method details.

Country of residence or purchase Compare with another country

References

  1. Roxarsone, inorganic arsenic, and other arsenic species in chicken: a U.S.-based market basket sample.. Nachman KE et al.. Environ Health Perspect 2013 · PMID 23694900 · DOI 10.1289/ehp.1206245
  2. Poultry Consumption and Arsenic Exposure in the U.S. Population.. Nigra AE et al.. Environ Health Perspect 2017 · PMID 27735790 · DOI 10.1289/EHP351
  3. Arsenic-based Animal Drugs and Poultry (FDA web page, last updated 29 April 2022). US Food and Drug Administration. FDA 2022
  4. Regulation (EC) No 1831/2003 on additives for use in animal nutrition (original text, Article 11 and recitals 25-26). European Parliament and Council. Official Journal of the EU (copy at legislation.gov.uk) 2003

← Back to overview